<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02250599</url>
  </required_header>
  <id_info>
    <org_study_id>ML29153</org_study_id>
    <nct_id>NCT02250599</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma</brief_title>
  <official_title>Multi-center, Randomized, Controlled, Open-label Study of Bevacizumab With Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel in Patients With Metastatic Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will be a randomized, control, multicenter phase II study of metastatic&#xD;
      nasopharyngeal carcinoma (NPC) treated with evacizumab (AVASTIN,Roch) with paclitaxel and&#xD;
      carboplatin regimen (TC+AVASTIN) or carboplatin/paclitaxel alone (TC). The population&#xD;
      consists of metastatic nasopharyngeal carcinoma (NPC) that failed the radical radiotherapy or&#xD;
      chemotherapy-naïve advanced NPC (stage IV). The effectiveness and side effects will be&#xD;
      evaluated according to RECIST 1.1 and NCI-CTC AE V4.0.TEORTC QLQ-C30 and EORTC QLQ-H&amp;N35 are&#xD;
      used to measure PRO outcome for this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nasopharyngeal carcinoma is vastly more common in East Asia, especially China has a high&#xD;
      incidence of it, and the number of new cases will account for more than 40% of the world&#xD;
      total . The disease involved population maybe more than 4 million in the world. More than&#xD;
      2700-3000 new nasopharyngeal carcinoma patients will be diagnosed in SUN YAT-SEN university&#xD;
      cancer center every year. It is most common in 40-50 years old adults and has been a top ten&#xD;
      (10th) malignant tumor in Chinese male which threaten human health and social economy.&#xD;
&#xD;
      Chemotherapy is the standard treatment of the advanced nasopharyngeal carcinoma.Several other&#xD;
      phase II study also confirmed the effectiveness of paclitaxel and carboplatin （TC） regimen in&#xD;
      advanced NPC, so it maybe a simple right choice.&#xD;
&#xD;
      Increasing expression of VEGF in serum associated with poor prognosis in metastatic&#xD;
      nasopharyngeal carcinoma. Agents that selectively target VEGF-A and its receptors have shown&#xD;
      significant antitumor effects in xenograft models of nasopharyngeal. Studies demonstrated&#xD;
      that bevacizumab（AVASTIN） administration with chemotherapy or chemoradiation is feasible in&#xD;
      patients with nasopharyngeal cancer. Bevacizumab can be safely combined with a range of&#xD;
      cytotoxic and other anticancer agents including TC regimen.&#xD;
&#xD;
      Evidence indicated a potential possibility that the TC+AVASTIN regimen may be superior than&#xD;
      TC regimen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR,CR+PR)</measure>
    <time_frame>3 years</time_frame>
    <description>Identified by investigators and independent radiologic review (IRC) respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate(DCR,CR+PR+SD)</measure>
    <time_frame>3 years</time_frame>
    <description>Identified by investigators and IRC respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Identified by IRC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Nasopharyngeal Neoplasms</condition>
  <arm_group>
    <arm_group_label>carboplatin and paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>carboplatin and paclitaxel :paclitaxel 175 mg/m2 IV and carboplatin AUC 6 IV on Day 1 of each 3-week cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AVASTIN and carboplatin and paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVASTIN and carboplatin and paclitaxel: Bevacizumab(AVASTIN) 7.5 mg/kg intravenously (IV) infusion on Day 1 of each 3-week cycle; paclitaxel 175 mg/m2 IV and carboplatin AUC 6 IV on Day 1 of each 3-week cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 175 mg/m2 IV Day 1 each 3-week cycle</description>
    <arm_group_label>AVASTIN and carboplatin and paclitaxel</arm_group_label>
    <arm_group_label>carboplatin and paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 7.5 mg/kg Day 1 each 3-week cycle</description>
    <arm_group_label>AVASTIN and carboplatin and paclitaxel</arm_group_label>
    <other_name>AVASTIN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC 6 IV Day 1 each 3-week cycle</description>
    <arm_group_label>AVASTIN and carboplatin and paclitaxel</arm_group_label>
    <arm_group_label>carboplatin and paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must meet the following criteria for study entry:&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0~1&#xD;
&#xD;
          -  Patients with a life expectancy&gt;12 weeks&#xD;
&#xD;
          -  Histologically proven NPC diagnosis&#xD;
&#xD;
          -  Metastatic nasopharyngeal carcinoma with evidence of unsuitable for local treatment(in&#xD;
             terms of some relevant therapy for anti-tumor like surgery, radiofrequency ablation,&#xD;
             transcatheter arterial chemoembolization(TACE) and radiotherapy(except palliative&#xD;
             radiotherapy for metastatic bone pain with appropriate radiation dosage without&#xD;
             influence to the hemogram),etc.)&#xD;
&#xD;
          -  Neoadjuvant or concurrent chemoradiotherapy was allowed, provided that the treatment&#xD;
             was completed at least 3 months before the start of study drug treatment&#xD;
&#xD;
             -≥1 measurable target based on RECIST criteria&#xD;
&#xD;
          -  Adequate bone marrow, hepatic and renal function, defined as follows within 1 weeks&#xD;
             prior to randomization&#xD;
&#xD;
          -  Patients must sign study specific informed consent prior to registration&#xD;
&#xD;
          -  Patient must have recovered (be &gt;28 days post-surgery) from the effects of surgery,&#xD;
             postoperative infection, and other complications before initial treatment with&#xD;
             bevacizumab&#xD;
&#xD;
          -  Systolic blood pressure ≤ 160 mmHg and diastolic pressure ≤ 90 mmHg within 7 days&#xD;
             prior to randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior systemic treatment for metastatic nasopharyngeal carcinoma&#xD;
&#xD;
          -  Preparing for receiving local treatment for metastatic nasopharyngeal carcinoma&#xD;
             (excluding palliative irradiation to release skeletal pain)&#xD;
&#xD;
          -  Prior treatment with bevacizumab or other agents specifically targeting VEGF&#xD;
&#xD;
          -  Patients with hemorrhage tendency including acute hemorrhage of digestive tract, nasal&#xD;
             bleeding （not including nasal epistaxis), continuous hemorrhagic disease or&#xD;
             Coagulation function disorder disease. Patients are using known NSAIDS to inhibit&#xD;
             platelets.&#xD;
&#xD;
          -  Patients with gross hemoptysis or hematemesis (defined as bright red blood of 1&#xD;
             teaspoon or more or frank clots within minimal or no phlegm per coughing episode)&#xD;
             within 4 weeks prior to registration; patients with incidental blood mixed with phlegm&#xD;
             are not excluded&#xD;
&#xD;
          -  Patients receiving other experimental therapeutic cancer treatment&#xD;
&#xD;
          -  Severe, active co-morbidity, defined as follows:&#xD;
&#xD;
             i.--Unstable angina and/or congestive heart failure or vascular (e.g. aortic aneurysm&#xD;
             requiring surgical repair or peripheral thrombosis) disease requiring hospitalization&#xD;
             within the last 12 months, or other cardiac compromise (e.g. an inadequately&#xD;
             controlled cardiac arrhythmia) that in the judgment of the investigator will preclude&#xD;
             the safe administration of a study drug; Patient must not show sign of recent&#xD;
             myocardial infarction or ischemia by the findings of S-T elevations of ≥ 2mm on an EKG&#xD;
             ii.--History of arterial thromboembolic events, venous thromboembolism &gt;NCI CTCAE&#xD;
             Grade 3, transient ischemic attack (TIA), cerebral vascular accident (CVA), transmural&#xD;
             myocardial infarction (MI), or hypertensive crisis or hypertensive encephalopathy&#xD;
             iii.--History of ongoing bleeding diathesis, hemorrhagic disorder, or coagulopathy&#xD;
             iv.--Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness&#xD;
             requiring hospitalization or precluding study therapy within 30 days prior to&#xD;
             registration v.--History of abdominal fistula, gastrointestinal perforation,&#xD;
             intra-abdominal abscess, or active GI bleeding within the last 6 months prior to&#xD;
             registration; vi.--Esophageal varices, non-healing ulcer, non-healing wound, or bone&#xD;
             fracture within the last 6 months prior to registration vii.--Active, untreated&#xD;
             infection and/or acute bacterial or fungal infection uiring intravenous antibiotics at&#xD;
             the time of registration viii.--Acquired Immune Deficiency Syndrome (AIDS) based upon&#xD;
             current CDC definition; ix. Hepatic insufficiency resulting in clinical jaundice&#xD;
             and/or coagulation defects x. - Minor surgical procedure including placement of a&#xD;
             vascular access device, within 2 days of the first study treatment&#xD;
&#xD;
          -  Patients currently (within 10 days of study enrollment) taking warfarin, heparin,&#xD;
             daily treatment with aspirin (&gt; 325 mg/day), or nonsteroidal anti-inflammatory&#xD;
             medications known to inhibit platelet function; treatment with dipyramidole,&#xD;
             ticlopidine, clopidogrel, or cilostazol&#xD;
&#xD;
          -  Pregnancy or women of childbearing potential and men who are sexually active and not&#xD;
             willing/able to use medically acceptable forms of contraception;&#xD;
&#xD;
          -  Prior allergic reaction to the study drug(s) involved in this protocol&#xD;
&#xD;
          -  Contraindication to Bevacizumab&#xD;
&#xD;
          -  Patients has another cancer history （not NPC）within 5 years before randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>li zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dongguan People's Hospital</name>
      <address>
        <city>Dongguan</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuefang Zhang</last_name>
      <email>674854955@qq.com</email>
    </contact>
    <investigator>
      <last_name>Chun Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology,Cancer Center of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>li zhang, MD</last_name>
      <phone>86-20-87343368</phone>
      <email>zhangli@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Tao Qin</last_name>
      <phone>13570396232</phone>
      <email>tantao@sysucc.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Yan Huang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuewu Huang</last_name>
      <email>doctorhxw@sina.com</email>
    </contact>
    <investigator>
      <last_name>Lizhu Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou University of Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuewu Huang, M.D.</last_name>
      <email>doctorhxw@sina.com</email>
    </contact>
    <investigator>
      <last_name>Lizhu Lin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangmen Central Hospital</name>
      <address>
        <city>Jiangmen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Wang</last_name>
      <email>39672979@qq.com</email>
    </contact>
    <investigator>
      <last_name>Xiaofan Ding</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruilian Xu</last_name>
      <email>xuruilian@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiyong Xu</last_name>
      <email>18978187401@189.cn</email>
    </contact>
    <investigator>
      <last_name>Guosheng Feng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hainan General Hospital</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanju Chen</last_name>
      <email>cyj-0001@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>August 26, 2014</study_first_submitted>
  <study_first_submitted_qc>September 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2014</study_first_posted>
  <last_update_submitted>December 28, 2015</last_update_submitted>
  <last_update_submitted_qc>December 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Li Zhang</investigator_full_name>
    <investigator_title>Profressor</investigator_title>
  </responsible_party>
  <keyword>Metastatic Nasopharyngeal Carcinoma</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

